

Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis

Yoko Kojima, ... , Tom Quertermous, Nicholas J. Leeper

J Clin Invest. 2019;129(5):2164-2164. <https://doi.org/10.1172/JCI129277>.

Corrigendum

Original citation: *J Clin Invest.* 2014;124(3):1083–1097. <https://doi.org/10.1172/JCI70391> Citation for this corrigendum: *J Clin Invest.* 2019;129(5):2164. <https://doi.org/10.1172/JCI129277> During the assembly of Figure 6A and Supplemental Figure 4C, incorrect flow cytometry plots were included. The authors were able to provide the original data, and a corrected version of Figure 6A appears below. The online version of the supplemental data has been updated with the corrected version of Supplemental Figure 4C. The authors regret the error.

Find the latest version:

<https://jci.me/129277/pdf>



Corrigendum

Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis

Yoko Kojima, Kelly Downing, Ramendra Kundu, Clint Miller, Frederick Dewey, Hope Lancero, Uwe Raaz, Ljubica Perisic, Ulf Hedin, Eric Schadt, Lars Maegdefessel, Tom Quertermous, and Nicholas J. Leeper

Original citation: *J Clin Invest.* 2014;124(3):1083–1097. <https://doi.org/10.1172/JCI70391>.

Citation for this corrigendum: *J Clin Invest.* 2019;129(5):2164. <https://doi.org/10.1172/JCI129277>.

During the assembly of Figure 6A and Supplemental Figure 4C, incorrect flow cytometry plots were included. The authors were able to provide the original data, and a corrected version of Figure 6A appears below. The online version of the supplemental data has been updated with the corrected version of Supplemental Figure 4C.

The authors regret the error.

